Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder

Next Previous
X
Search
Trial Profile

A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/trazodone (Primary) ; Bupropion
  • Indications Decreased libido
  • Focus Therapeutic Use
  • Acronyms PURPLE
  • Sponsors S1 Biopharma

    • Most Recent Events

    • 04 Jan 2019 According to a S1 Biopharma media release, expanded analysis of Phase 2a data will be presented at during the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Society for Sexual Medicine (ISSM) Joint Meeting 2019.
    • 27 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Mar 2014 Results data for the phase IIa part of this trial are expected in the second quarter of 2014, according to a S1 Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top